|
DE69627195T2
(de)
|
1995-11-01 |
2004-01-29 |
Novartis Ag |
Purinderivate und verfahren zu ihrer herstellung
|
|
FR2741881B1
(fr)
*
|
1995-12-01 |
1999-07-30 |
Centre Nat Rech Scient |
Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
|
|
US5866702A
(en)
*
|
1996-08-02 |
1999-02-02 |
Cv Therapeutics, Incorporation |
Purine inhibitors of cyclin dependent kinase 2
|
|
US6794390B2
(en)
*
|
1996-08-02 |
2004-09-21 |
Cv Therapeutics, Inc. |
Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
|
|
US6790958B2
(en)
*
|
1996-08-02 |
2004-09-14 |
Robert T. Lum |
Purine inhibitors of cyclin dependent kinase 2 & IKBA
|
|
US6495579B1
(en)
|
1996-12-02 |
2002-12-17 |
Angiotech Pharmaceuticals, Inc. |
Method for treating multiple sclerosis
|
|
CA2287531A1
(en)
*
|
1997-03-03 |
1998-09-11 |
Board Of Regents, The University Of Texas System |
Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
|
|
EP1003746A1
(en)
*
|
1997-08-07 |
2000-05-31 |
The Regents Of The University Of California |
Purine inhibitor of protein kinases, g proteins and polymerases
|
|
JP2001515722A
(ja)
*
|
1997-09-05 |
2001-09-25 |
クロップデザイン エヌ．ブイ． |
植物細胞周期蛋白質を調節する方法および手段ならびに植物細胞増殖の制御におけるそれらの使用
|
|
US7265267B1
(en)
|
1997-09-16 |
2007-09-04 |
Cropdesign N.V. |
Cyclin-dependent kinase inhibitors and uses thereof
|
|
AU754803B2
(en)
*
|
1997-09-16 |
2002-11-28 |
Cropdesign N.V. |
Cyclin-dependent kinase inhibitors and uses thereof
|
|
US6710227B1
(en)
|
1998-09-16 |
2004-03-23 |
Cropdesign N.V. |
Cyclin-dependent kinase inhibitors and uses thereof
|
|
EP0911634A1
(en)
*
|
1997-10-24 |
1999-04-28 |
Het Nederlands Kanker Instituut |
Pharmaceutical uses of CDK-2 regulators
|
|
CA2307171A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Cropdesign N.V. |
A novel mitogenic cyclin and uses thereof
|
|
US6642231B2
(en)
*
|
1998-02-26 |
2003-11-04 |
Aventis Pharmaceuticals Inc. |
6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
|
|
PT1056744E
(pt)
*
|
1998-02-26 |
2004-03-31 |
Aventis Pharma Inc |
2-¬trans-(4-aminociclo-hexil)amino|purinas 6,9-dissubstituidas
|
|
CN1128149C
(zh)
*
|
1998-02-26 |
2003-11-19 |
阿旺蒂斯制药公司 |
6,9－二取代的2－[反－(4－氨基环己基)氨基]嘌呤
|
|
US6479487B1
(en)
|
1998-02-26 |
2002-11-12 |
Aventis Pharmaceuticals Inc. |
6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
|
|
US6703395B2
(en)
*
|
1998-03-04 |
2004-03-09 |
Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic |
Cyclin dependent kinase inhibitor
|
|
US6221873B1
(en)
*
|
1998-03-04 |
2001-04-24 |
Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic |
Cyclin dependent kinase inhibitor
|
|
GB9806739D0
(en)
*
|
1998-03-28 |
1998-05-27 |
Univ Newcastle Ventures Ltd |
Cyclin dependent kinase inhibitors
|
|
US6664439B1
(en)
|
1998-04-28 |
2003-12-16 |
The Procter & Gamble Company |
Absorbent articles with distribution materials positioned underneath storage material
|
|
WO2000021550A2
(en)
*
|
1998-10-13 |
2000-04-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating neurodegenerative diseases
|
|
AU1559400A
(en)
*
|
1998-12-04 |
2000-06-26 |
Cropdesign N.V. |
Method to identify regulators of cdk activity
|
|
CZ27399A3
(cs)
*
|
1999-01-26 |
2000-08-16 |
Ústav Experimentální Botaniky Av Čr |
Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
|
|
DK1150982T3
(da)
*
|
1999-02-01 |
2005-12-27 |
Cv Therapeutics Inc |
Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
|
|
AU2004200192B2
(en)
*
|
1999-02-01 |
2006-11-16 |
Gilead Palo Alto, Inc. |
Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
|
|
EP1026251A3
(en)
*
|
1999-02-03 |
2000-09-06 |
Pfizer Products Inc. |
Transgenic animals expressing human P25
|
|
GB9903762D0
(en)
|
1999-02-18 |
1999-04-14 |
Novartis Ag |
Organic compounds
|
|
US6627633B2
(en)
*
|
1999-03-17 |
2003-09-30 |
Albany Molecular Research, Inc. |
6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
|
|
US6969720B2
(en)
|
1999-03-17 |
2005-11-29 |
Amr Technology, Inc. |
Biaryl substituted purine derivatives as potent antiproliferative agents
|
|
FR2793794B1
(fr)
*
|
1999-05-21 |
2001-07-27 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
|
|
US20030187261A1
(en)
*
|
2000-01-07 |
2003-10-02 |
Libor Havlicek |
Purine derivatives, process for their preparation and use thereof
|
|
WO2001055148A1
(en)
*
|
2000-01-27 |
2001-08-02 |
Warner-Lambert Company |
Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
|
|
FR2806626B1
(fr)
*
|
2000-03-22 |
2003-11-28 |
Centre Nat Rech Scient |
Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
|
|
KR100423899B1
(ko)
|
2000-05-10 |
2004-03-24 |
주식회사 엘지생명과학 |
세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
|
|
US20040254094A1
(en)
*
|
2000-10-11 |
2004-12-16 |
The Trustees Of University Of Pennsylvania And Board Of Regents |
Suppression of cyclin kinase activity for prevention and treatment of infections
|
|
US6861524B2
(en)
|
2000-10-31 |
2005-03-01 |
Aventis Pharmaceuticals Inc. |
Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
|
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
|
DE60205376T2
(de)
*
|
2001-06-27 |
2006-04-06 |
Cyclacel Ltd. |
2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
|
|
US6667311B2
(en)
|
2001-09-11 |
2003-12-23 |
Albany Molecular Research, Inc. |
Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
|
|
US6812232B2
(en)
|
2001-09-11 |
2004-11-02 |
Amr Technology, Inc. |
Heterocycle substituted purine derivatives as potent antiproliferative agents
|
|
US7176312B2
(en)
*
|
2001-10-12 |
2007-02-13 |
The Scripps Research Institute |
Kinase inhibitor scaffolds and methods for their preparation
|
|
US20050222054A1
(en)
*
|
2002-03-27 |
2005-10-06 |
Cyclacel Limited |
Combination comprising a CDK inhibitor and doxorubicin
|
|
CA2488562A1
(en)
*
|
2002-06-27 |
2004-01-08 |
F. Hoffmann-La Roche Ag |
Synthesis of purine derivatives
|
|
GB0219052D0
(en)
|
2002-08-15 |
2002-09-25 |
Cyclacel Ltd |
New puring derivatives
|
|
GB0219054D0
(en)
|
2002-08-15 |
2002-09-25 |
Cyclacel Ltd |
New purine derivatives
|
|
GB0219746D0
(en)
*
|
2002-08-23 |
2002-10-02 |
Inst Of Ex Botany Ascr |
Azapurine derivatives
|
|
US20050226879A1
(en)
*
|
2002-09-17 |
2005-10-13 |
Ulmann Katharine S |
Methods and compositions related to inhibiting nuclear envelope breakdown
|
|
AU2003276467A1
(en)
*
|
2002-11-06 |
2004-06-07 |
Cyclacel Limited |
Combination comprising docetaxel and a cdk inhibitor
|
|
MXPA05004920A
(es)
*
|
2002-11-06 |
2005-08-18 |
Cyclacel Ltd |
Combinacion que comprende un inhibidor cdk y cisplatin.
|
|
GB0225873D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Cyclacel Ltd |
Combination
|
|
ATE409484T1
(de)
*
|
2002-12-17 |
2008-10-15 |
Centre Nat Rech Scient |
Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP1444982A1
(de)
*
|
2003-02-06 |
2004-08-11 |
Merckle Gmbh |
Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
|
|
GB0307640D0
(en)
*
|
2003-04-02 |
2003-05-07 |
Cyclacel Ltd |
Markers
|
|
GB0315259D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Cyclacel Ltd |
Use
|
|
US20070287718A1
(en)
*
|
2003-11-06 |
2007-12-13 |
Green Simon R |
Methods for the Treatment of Multiple Myeloma Using Roscovitine
|
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
|
CA2576159A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Cyclacel Limited |
Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
|
|
WO2006040036A1
(en)
|
2004-10-13 |
2006-04-20 |
F. Hoffmann-La Roche Ag |
Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
|
|
FR2876583B1
(fr)
*
|
2004-10-15 |
2007-04-13 |
Centre Nat Rech Scient Cnrse |
Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
|
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
|
KR20110010813A
(ko)
*
|
2005-10-14 |
2011-02-07 |
에프. 호프만-라 로슈 아게 |
5-(2-클로로페닐)-1,2-디히드로-7-플루오로-8-메톡시-3-메틸-피라졸로[3,4-ｂ][1,4] 벤조디아제핀의 투여 섭생
|
|
US20070110751A1
(en)
*
|
2005-10-25 |
2007-05-17 |
Maclellan Robb |
Compositions and methods for reducing infarct size
|
|
JP5486808B2
(ja)
|
2005-11-30 |
2014-05-07 |
アッヴィ・インコーポレイテッド |
アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
|
|
EP2289909B1
(en)
|
2005-11-30 |
2014-10-29 |
AbbVie Inc. |
Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
FR2899107B1
(fr)
*
|
2006-03-30 |
2008-06-13 |
Neurokin Entpr Unipersonnelle |
Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
|
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
DK2076268T3
(da)
*
|
2006-10-19 |
2013-04-22 |
Genzyme Corp |
Roscovitin til behandling af visse cystiske sygdomme
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
EP2142545A1
(en)
|
2007-03-28 |
2010-01-13 |
NeuroSearch A/S |
Purinyl derivatives and their use as potassium channel modulators
|
|
NZ579248A
(en)
*
|
2007-03-28 |
2011-08-26 |
Neurosearch As |
Purinyl derivatives and their use as potassium channel modulators
|
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
GB0706632D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
New purine derivatives
|
|
CZ300774B6
(cs)
*
|
2007-10-05 |
2009-08-05 |
Univerzita Palackého |
Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny
|
|
BRPI0820722A2
(pt)
|
2007-12-20 |
2015-06-16 |
Novartis Ag |
Derivados de tiazol usados como inibidores de pi 3 cinases
|
|
JP2011207764A
(ja)
*
|
2008-07-29 |
2011-10-20 |
Univ Of Tokyo |
Ｃｄｋ阻害剤によるｃ型肝炎ウイルスの複製抑制
|
|
PE20100362A1
(es)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
|
CZ302122B6
(cs)
*
|
2009-01-28 |
2010-10-20 |
Univerzita Palackého v Olomouci |
Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
|
|
CZ302623B6
(cs)
*
|
2009-04-22 |
2011-08-03 |
Univerzita Palackého |
Oxalátokomplexy platiny s deriváty N6-benzyladeninu, zpusob jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
|
|
FR2945747A1
(fr)
|
2009-05-25 |
2010-11-26 |
Centre Nat Rech Scient |
Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
JP2013523182A
(ja)
|
2010-04-15 |
2013-06-17 |
アボット・ラボラトリーズ |
アミロイドベータ結合タンパク質
|
|
US9376664B2
(en)
|
2010-06-14 |
2016-06-28 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
CN105348387B
(zh)
|
2010-08-14 |
2020-08-25 |
Abbvie 公司 |
β淀粉样蛋白结合蛋白
|
|
ES2611885T3
(es)
|
2011-01-31 |
2017-05-11 |
Novartis Ag |
Derivados heterocíclicos novedosos
|
|
WO2012142029A2
(en)
|
2011-04-10 |
2012-10-18 |
Florida A&M University |
Serms for the treatment of estrogen receptor-mediated disorders
|
|
EP2561867A1
(en)
|
2011-08-22 |
2013-02-27 |
Lead Discovery Center GmbH |
CDK9 inhibitors in the treatment of midline carcinoma
|
|
EP2562265A1
(en)
|
2011-08-22 |
2013-02-27 |
Lead Discovery Center GmbH |
Susceptibility to selective CDK9 inhibitors
|
|
PT2771342T
(pt)
|
2011-10-28 |
2016-08-17 |
Novartis Ag |
Derivados de purina e o seu uso no tratamento de doença
|
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
|
EP2874631A1
(en)
|
2012-05-15 |
2015-05-27 |
Cyclacel Limited |
Dosage regimen for sapacitabine and seliciclib
|
|
JP6381523B2
(ja)
|
2012-05-16 |
2018-08-29 |
ノバルティス アーゲー |
Ｐｉ−３キナーゼ阻害剤の投与レジメン
|
|
MX2014014872A
(es)
|
2012-06-26 |
2015-08-06 |
Saniona Aps |
Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
|
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
HUE057092T2
(hu)
|
2013-12-06 |
2022-04-28 |
Novartis Ag |
Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje
|
|
EP2907514B1
(en)
|
2014-02-17 |
2019-10-23 |
Manros Therapeutics |
Purine derivative compounds for medical use
|
|
US10555931B2
(en)
|
2014-05-28 |
2020-02-11 |
Piramal Enterprises Limited |
Pharmaceutical combination for the treatment of cancer
|
|
CN108472289A
(zh)
|
2015-11-02 |
2018-08-31 |
诺华股份有限公司 |
磷脂酰肌醇3-激酶抑制剂的给药方案
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
US10729692B2
(en)
*
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
|
EP3606536A4
(en)
*
|
2017-04-04 |
2020-12-16 |
University of Miami |
INDICATIVE BIOMARKERS OF PROSTATE CANCER AND RELATED TREATMENT
|
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
|
CN112794852B
(zh)
*
|
2021-01-12 |
2021-11-30 |
江汉大学 |
一种含硒有机化合物及其制备方法与应用
|
|
CN112794853B
(zh)
*
|
2021-01-12 |
2021-11-30 |
江汉大学 |
一种有机硒化合物及其制备方法与应用
|